Member Info for Sangijuelas1

This has just gone up on the Guardian. I wanted to Email the journalist but seems to only be on Twitter.
I don't use it but if anyone else is she might be interested in 4D
https://www.theguardian.com/society/2021/feb/04/faecal-transplants-could-help-patients-with-form-of-skin-cancer

I am concerned for Axe. Invested in small pharma and wants companies to do first in human trials on large numbers of patients.

Axe, it's you that's making yourself lookf incredibly stupid whilst attempting to appear knowledgeable . A P1 trial is always done with small numbers as it's primarily about safety.

You are not going to run a safety trial on a 1000 patients as if not safe you would be in a lot of trouble.

Article also mentions Zacs Small Cap research have initiated coverage

Seriously? You invested in a developmental pharma company and after 6 months you are expecting to have made a big profit.
Are you for real?

US premarket is down 6%

Is clearly a shorter. Hundreds of posts on EZY despite not being invested

I think you will find Sharebel said this when the offer dropped to 150. I also tried multiple times and it would only let me buy once the offer was back to 152.

TO at £10 a share could be RNSd and you'd watch it rocket to 182 before dropping down again to 148.

Yeah but could also be what's keeping a lid on it. If the shelf reg enables Tils to do a rapid fund raise when the price is higher investors that want in will not want to bid the price up

Thats what Weiner said on Bloomberg

Market must be anticipating a fund raise. The P2 isn't going to pay for itself.

I am still learning about the company. One thing I liked that I heard yesterday was that the nasal drops require a very small amount of the MAB compared to infusion, as MABs are generally costly and difficult to produce in large quantities.

Would also mean production scale up would be a lot easier.

Same here

4D had a biotherapeutic treatment for covid that similarly looked to reduce lung inflammation.

It was registered quickly here and set up but then was unable to get access to any infected patients as all resources for trials were diverted to vaccine trials.

Because the company doesn't need to be told how to conduct its business by its shareholders.

They are looking to do the P2 in the US and I am sure they are fully aware of the potential to do a trial in the UK.

Please don't

That many people's cancer treatments are on hold and knowing that 4D has something that could potentially help some of them.

3 of the part A continue on the study for over 18 months with further target tumour reductions or stable disease.
So from the original trial of severely ill patients with no treatment options a quarter are stable or improving.
Massive

I like this bit

This will support 4D pharma's continued productive engagement with regulatory authorities to develop the clinical strategy to bring this novel therapeutic to patients suffering from a range of cancers."